Replies to post #35006 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

DCVax-L is expecting higher numbers than Novocure obtained in its phase III trial. Even NWBO's indeterminate group from their informational arm of potentialy rapid progressors already beat Novocure's results that excluded rapid progressors, and the rapid progressors combined with the potentially rapid progressors came within a month of Novocure's results that excluded rapid progressors.

[koman]

I highly doubt that Novocure's EF14 treatment will effect any of the current trials by various companies in the field of nGBM because it seems that the FDA will want to give doctors and patients more options to choose and IMO Novocure's system will not be the choice of most doctors ONCE they have those options available.